__NUXT_JSONP__("/drugs/Selective_Human_Estrogen-receptor_Alpha_Partial_Agonist_TTC-352", (function(a,b,c,d){return {data:[{drug:{slug:b,emaEpar:[],fdaDrugLabel:[],id:b,nciThesaurus:{casRegistry:a,chebiId:a,chemicalFormula:a,definition:"A benzothiophene and orally bioavailable selective human estrogen receptor alpha (ERalpha; ESR1; ERa) partial agonist (ShERPA), with potential antineoplastic activity. Upon administration, TTC-352 mimics the naturally-occurring 17beta-estradiol (E2) and targets and binds to ERa located in the nucleus. This causes translocation of ERa to extranuclear sites. Nuclear export of ERa prevents normal ER-mediated signaling and inhibits proliferation of ER-positive tumor cells. TTC-352 causes tumor regression of tamoxifen (TAM)-resistant (TR) tumor cells which often overexpress protein kinase C alpha (PKCalpha; PKCa). PKCa expression is associated with poor patient survival and breast cancer aggressiveness and may predict tumor responses to E2, E2-like compounds and ShERPAs. Unlike E2 and E2-like compounds, TTC-352 does not cause endometrial proliferation.",fdaUniiCode:"65ILH3Y0MI",identifier:"C150363",preferredName:c,semanticType:"Pharmacologic Substance",subclassOf:["C483"],synonyms:["3-(4-Fluorophenyl)-2-(4-hydroxyphenoxy)benzo[b]thiophen-6-ol","ERa Partial Agonist TTC-352","SEM TTC-352","Selective Estrogen Mimic TTC-352","Selective Estrogen Modulator TTC-352",c,"ShERPA TTC-352","TTC 352","TTC-352"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FSelective_Human_Estrogen-receptor_Alpha_Partial_Agonist_TTC-352",extension:".json",createdAt:d,updatedAt:d}}],fetch:{},mutations:void 0}}("","Selective_Human_Estrogen-receptor_Alpha_Partial_Agonist_TTC-352","Selective Human Estrogen-receptor Alpha Partial Agonist TTC-352","2021-10-30T13:33:21.493Z")));